Clinical Trial

Tebentafusp-tebn With LDT in Metastatic UM

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A\*0201 positive patients with metastatic uveal melanoma. In Part 1 of the study, the Prinicipal Investigator will investigate the safety and efficacy of tebentafusp-tebn in combination with hepatic IE in patients with a low to moderate hepatic disease burden. In Part 2, the study will investigate the efficacy of tebentafusp-tebn in combination with TACE in patients with bulky hepatic disease.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-10-01; most recent amendment 2026-07-17.
Status change: Not Yet Recruiting → Recruiting 2025-11-21
Trial Details
NCT Number NCT06626516
Lead Sponsor Thomas Jefferson University
Collaborators: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Wills Eye
Conditions Metastatic Uveal Melanoma
Enrollment 109 participants
Start Date 2025-10-15
Primary Completion 2030-10 (estimated)
Study Completion 2032-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-21